1
|
Crooks CJ, West J, Morling JR, Simmonds M, Juurlink I, Cruickshank S, Briggs S, Hammond-Pears S, Shaw D, Card TR, Fogarty AW. Pulse oximetry has limited utility in identifying potential patients for long-term oxygen therapy. Int J Tuberc Lung Dis 2024; 28:253-255. [PMID: 38659138 DOI: 10.5588/ijtld.23.0491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2024] Open
Affiliation(s)
- C J Crooks
- Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK, Nottingham University Hospitals NHS Trust, UK
| | - J West
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK, Nottingham University Hospitals NHS Trust, UK, Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK, East Midlands Academic Health Science Network, University of Nottingham, Nottingham, UK
| | - J R Morling
- Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK
| | - M Simmonds
- Nottingham University Hospitals NHS Trust, UK
| | - I Juurlink
- Nottingham University Hospitals NHS Trust, UK
| | | | - S Briggs
- Nottingham University Hospitals NHS Trust, UK
| | - S Hammond-Pears
- Nottingham University Hospitals NHS Trust, UK, East Midlands Academic Health Science Network, University of Nottingham, Nottingham, UK
| | - D Shaw
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK, Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham
| | - T R Card
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK, Nottingham University Hospitals NHS Trust, UK, Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK
| | - A W Fogarty
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK, Nottingham University Hospitals NHS Trust, UK, Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK
| |
Collapse
|
2
|
Barnsley H, Robertson S, Cruickshank S, McNair HA. Radiographer training for screening of patients referred for Magnetic Resonance Imaging: A scoping review. Radiography (Lond) 2024; 30:843-855. [PMID: 38579383 DOI: 10.1016/j.radi.2024.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 03/12/2024] [Accepted: 03/19/2024] [Indexed: 04/07/2024]
Abstract
INTRODUCTION Strict safety practices are essential to ensure the safety of patients and staff in Magnetic Resonance Imaging (MRI). Training regarding the fundamentals of MRI safety is well-established and commonly agreed upon. However, more complex aspect of screening patients, such as image review or screening of unconscious patients/patients with communication difficulties is less well discussed. The current UK and USA guidelines do not suggest the use of communication training for MRI staff nor indicate any training to encourage reviewing images in the screening process. This review aims to map the current guidance regarding safety and patient screening training for MRI diagnostic and therapeutic radiographers. METHODS A systematic search of PubMed, Trip Medical database and Radiography journal was conducted. Studies were chosen based on the review objectives and pre-determined inclusion/exclusion criteria using the PRISMA-ScR framework. RESULTS Twenty-four studies were included in the review, which identified some key concepts including MRI safety training and delivery methods, screening and communication, screening of unconscious or non-ambulatory patients and the use of imaging. CONCLUSION Training gaps lie within the more complex elements of screening such as the inclusiveness of question phrasing, particularly to the neurodivergent population, how we teach radiographers to screen unconscious/unresponsive patients and using imaging to detect implants. IMPLICATIONS FOR PRACTICE The consequences of incomplete or inaccurate pre-MRI safety screening could be the introduction of unexpected implants into the scanner or forgoing MRI for a less desirable modality. The development of enhanced training programs in implant recognition using imaging and communication could complement existing training.
Collapse
Affiliation(s)
- H Barnsley
- The Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK
| | - S Robertson
- The Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK
| | - S Cruickshank
- The Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK
| | - H A McNair
- The Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK; The Institute of Cancer Research, UK.
| |
Collapse
|
3
|
Crooks CJ, West J, Morling JR, Simmonds M, Juurlink I, Briggs S, Cruickshank S, Hammond-Pears S, Shaw D, Card TR, Fogarty AW. Differential pulse oximetry readings between ethnic groups and delayed transfer to intensive care units. QJM 2023; 116:63-67. [PMID: 36066450 PMCID: PMC9928225 DOI: 10.1093/qjmed/hcac218] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 08/31/2022] [Accepted: 09/01/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Pulse oximeters are widely used to monitor blood oxygen saturations, although concerns exist that they are less accurate in individuals with pigmented skin. AIMS This study aimed to determine if patients with pigmented skin were more severely unwell at the period of transfer to intensive care units (ICUs) than individuals with White skin. METHODS Using data from a large teaching hospital, measures of clinical severity at the time of transfer of patients with COVID-19 infection to ICUs were assessed, and how this varied by ethnic group. RESULTS Data were available on 748 adults. Median pulse oximetry demonstrated similar oxygen saturations at the time of transfer to ICUs (Kruskal-Wallis test, P = 0.51), although median oxygen saturation measurements from arterial blood gases at this time demonstrated lower oxygen saturations in patients classified as Indian/Pakistani ethnicity (91.6%) and Black/Mixed ethnicity (93.0%), compared to those classified as a White ethnicity (94.4%, Kruskal-Wallis test, P = 0.005). There were significant differences in mean respiratory rates in these patients (P < 0.0001), ranging from 26 breaths/min in individuals with White ethnicity to 30 breaths/min for those classified as Indian/Pakistani ethnicity and 31 for those who were classified as Black/Mixed ethnicity. CONCLUSIONS These data are consistent with the hypothesis that differential measurement error for pulse oximeter readings negatively impact on the escalation of clinical care in individuals from other than White ethnic groups. This has implications for healthcare in Africa and South-East Asia and may contribute to differences in health outcomes across ethnic groups globally.
Collapse
Affiliation(s)
- C J Crooks
- Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham NG7 2UH, UK
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
| | - J West
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham NG7 2UH, UK
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
- Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK
- East Midlands Academic Health Science Network, University of Nottingham, Nottingham NG7 2TU, UK
| | - J R Morling
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham NG7 2UH, UK
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
- Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK
| | - M Simmonds
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
| | - I Juurlink
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
| | - S Briggs
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
| | - S Cruickshank
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
| | - S Hammond-Pears
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
- East Midlands Academic Health Science Network, University of Nottingham, Nottingham NG7 2TU, UK
| | - D Shaw
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
- Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK
| | - T R Card
- NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham NG7 2UH, UK
- Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
- Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK
| | - A W Fogarty
- Address correspondence to Dr A.W. Fogarty, NIHR Nottingham Biomedical Research Centre (BRC), Nottingham City Hospital, Nottingham NG5 1PB, UK.
| |
Collapse
|
4
|
Muls A, Georgopoulou S, Hainsworth E, Hartley B, O'Gara G, Stapleton S, Cruickshank S. The psychosocial and emotional experiences of cancer patients during the COVID-19 pandemic: A systematic review. Semin Oncol 2022; 49:371-382. [PMID: 36089413 PMCID: PMC9393184 DOI: 10.1053/j.seminoncol.2022.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 07/29/2022] [Accepted: 08/13/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND COVID-19 was declared a pandemic by the World Health Organization on March 11th, 2020. Global social lockdowns were instigated to reduce spread and prevent health-services from becoming overwhelmed. People having treatment for cancer are known to have heightened psychological/emotional burden. The combined impact of managing pandemic regulations alongside this may present additional burden. The purpose of this systematic review is to examine current evidence of the psychological and emotional impact of COVID-19 on people with cancer, early in the pandemic. METHODS Five electronic databases were searched (Embase, Global Health, HMIC, PsychINFO, CINAHL) from September 2019 to October 2021. Qualitative, quantitative and mixed-method primary research studies exploring emotional and psychological impacts of COVID-19 on cancer patients, limited to English language, were included. Quality appraisal was conducted using the MMAT. RESULTS Fifty-one papers, with 27,356 people from 21 countries treated for cancer, were included. 43 studies were quantitative with a survey method approach, six studies qualitative and four used a mixed methods design. MMAT score was mostly two or three. Four themes were identified: Emotional aspects and Quality of Life; Psychosocial aspects; Impact of COVID-19 on self; Impact of COVID-19 on cancer, with themes overlapping. CONCLUSION Whilst emotional/psychological impacts such as anxiety, isolation, employment fears, and uncertainty about the future were potentially universal concerns early in the pandemic, they may have been particularly acute for people living with cancer and represent complex, overlapping factors. As COVID-19 continues to impact health-services and society, it is important to focus on any ongoing impact to the experience of cancer patients. Most of the studies reviewed used tools that do not provide deeper understanding of how and why emotional states of people with cancer were affected. Further qualitative work may reveal patterns of what was unique to cancer patients during the pandemic, compared to general populations.
Collapse
|
5
|
Robertson S, Olanloye E, Hon Y, England A, McNair H, Cruickshank S. Are radiographers suffering from symptoms of compassion fatigue due to occupational stress: A systematic review. Radiography (Lond) 2022; 28:857-864. [DOI: 10.1016/j.radi.2022.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 03/04/2022] [Accepted: 04/03/2022] [Indexed: 10/18/2022]
|
6
|
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan S, Loong H, Bauer T, Kim Y, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, Brose M, Pennell N, Weiss J, Matos I, Peled N, Cho B, Ohe Y, Reckamp K, Boni V, Satouchi M, Falchook G, Akerley W, Daga H, Sakamoto T, Patel J, Lakhani N, Barlesi F, Burkard M, Zhu V, Moreno Garcia V, Medioni J, Matrana M, Rolfo C, Lee D, Nechushtan H, Johnson M, Velcheti V, Nishio M, Toyozawa R, Ohashi K, Song L, Han J, Spira A, De Braud F, Staal Rohrberg K, Takeuchi S, Sakakibara J, Waqar S, Kenmotsu H, Wilson F, B.Nair, Olek E, Kherani J, Ebata K, Zhu E, Nguyen M, Yang L, Huang X, Cruickshank S, Rothenberg S, Solomon B, Goto K, Subbiah V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.059] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019; 30:325-331. [PMID: 30624546 PMCID: PMC6386027 DOI: 10.1093/annonc/mdy539] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours harbouring NTRK gene fusions. PATIENTS AND METHODS This multi-centre, phase I dose escalation study enrolled adults with metastatic solid tumours, regardless of NTRK gene fusion status. Key inclusion criteria included evaluable and/or measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Larotrectinib was administered orally once or twice daily, on a continuous 28-day schedule, in increasing dose levels according to a standard 3 + 3 dose escalation scheme. The primary end point was the safety of larotrectinib, including dose-limiting toxicity. RESULTS Seventy patients (8 with tumours with NTRK gene fusions; 62 with tumours without a documented NTRK gene fusion) were enrolled to 6 dose cohorts. There were four dose-limiting toxicities; none led to study drug discontinuation. The maximum tolerated dose was not reached. Larotrectinib-related adverse events were predominantly grade 1; none were grade 4 or 5. The most common grade 3 larotrectinib-related adverse event was anaemia [4 (6%) of 70 patients]. A dose of 100 mg twice daily was recommended for phase II studies based on tolerability and antitumour activity. In patients with evaluable TRK fusion cancer, the objective response rate by independent review was 100% (eight of the eight patients). Eight (12%) of the 67 assessable patients overall had an objective response by investigator assessment. Median duration of response was not reached. Larotrectinib had limited activity in tumours with NTRK mutations or amplifications. Pharmacokinetic analysis showed exposure was generally proportional to administered dose. CONCLUSIONS Larotrectinib was well tolerated, demonstrated activity in all patients with tumours harbouring NTRK gene fusions, and represents a new treatment option for such patients. CLINCALTRIALS.GOV NUMBER NCT02122913.
Collapse
Affiliation(s)
- D S Hong
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
| | - T M Bauer
- Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, USA
| | - J J Lee
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA
| | - A Dowlati
- Department of Medicine-Hematology and Oncology, UH Cleveland Medical Center, Cleveland, USA
| | - M S Brose
- Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, USA
| | - A F Farago
- Department of Medicine, Massachusetts General Hospital, Boston, USA
| | - M Taylor
- The Knight Cancer Institute, Oregon Health & Science University, Portland, USA
| | - A T Shaw
- Department of Medicine, Massachusetts General Hospital, Boston, USA
| | - S Montez
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - F Meric-Bernstam
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S Smith
- Loxo Oncology, South San Francisco, USA
| | - B B Tuch
- Loxo Oncology, South San Francisco, USA
| | - K Ebata
- Loxo Oncology, South San Francisco, USA
| | | | - M C Cox
- Loxo Oncology, South San Francisco, USA
| | - H A Burris
- Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, USA
| | - R C Doebele
- Department of Medicine, University of Colorado Cancer Center, Aurora, USA
| |
Collapse
|
8
|
Tan D, Lassen U, Albert C, Kummar S, van Tilburg C, Dubois S, Geoerger B, Mascarenhas L, Federman N, Basu-Mallick A, Doz F, Berlin J, Oh DY, Bielack S, McDermott R, Cruickshank S, Ku N, Cox M, Drilon A, Hong D. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy430] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Lassen U, Albert C, Kummar S, van Tilburg C, Dubois S, Geoerger B, Mascarenhas L, Federman N, Schilder R, Doz F, Berlin J, Oh DY, Bielack S, McDermott R, Tan D, Cruickshank S, Ku N, Cox M, Drilon A, Hong D. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.397] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Farago A, Kummar S, Ibabekci S, Corsi-Travali S, Cruickshank S, Cox M, Ku N, Drilon A. P1.13-40 Rapid, Robust and Durable Responses to Larotrectinib in Patients with TRK Fusion Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.897] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Nathenson M, Demetri G, Lassen U, Hong D, Boni V, Deeken J, Dowlati A, Cox M, Ku N, Cruickshank S, Qamoos H, Drilon A. Activity of larotrectinib in patients with TRK fusion GI malignancies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Stones SR, Verstappen S, Cruickshank S. 50. The development and evaluation of an interactive health communication application to promote self-management in young people diagnosed with juvenile idiopathic arthritis: a pilot study. Rheumatology (Oxford) 2017. [DOI: 10.1093/rheumatology/kex390.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Velcheti V, Bauer T, Subbiah V, Cabanillas M, Lakhani N, Wirth L, Oxnard G, Shah M, Sherman E, Smith S, Eary T, Cruickshank S, Tuch B, Ebata K, Nguyen M, Corsi-Travali S, Rothenberg S, Drilon A. OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.399] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Alhubail M, Cruickshank S, McBain A, O’Neill C. 700 Lactobacillus rhamnosus GG and its lysate protects human epidermal keratinocytes from the toxic effect of specific wound pathogens. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Drilon A, Bauer T, Subbiah V, Cabanillas M, Lahkani N, Wirth L, Oxnard G, Smith S, Eary T, Cruickshank S, Nguyen M, Rothenberg S. A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Forero A, Stroyakovskiy D, Cha E, Cruickshank S, Hasapidis J, Meyers ML, Slamon DJ. Abstract OT2-01-12: ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-12] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Atezolizumab, a humanized anti-PDL1 antibody, has shown encouraging single agent activity in triple negative breast cancer. Entinostat is an oral, class I selective histone deacetylase (HDAC) inhibitor. In animal models, entinostat has been shown to selectively reduce immunosuppressive myeloid derived suppressor cells (MDSCs) and regulatory T cells (Tregs), enhancing response to immune checkpoint blockade. It is hypothesized that entinostat in combination with atezolizumab will show improved efficacy compared to atezolizumab alone.
Trial Design: ENCORE 602 is a Phase 1b/2 study evaluating the combination of entinostat plus atezolizumab in patients with aTNBC. The study has 2 phases: an open-label Dose Determination Phase (Phase 1b) followed by Phase 2. The objective of the Dose Determination Phase is to establish the recommended Phase 2 dose (RP2D) of weekly entinostat when given in combination with atezolizumab 1200 mg every 3 weeks. Phase 2 will evaluate the efficacy and safety of entinostat at the RP2D with atezolizumab in patients with aTNBC in a randomized (1:1), double-blind, placebo-controlled setting. The randomization will be stratified by geographic location (US vs ex-US).
Key Eligibility Criteria: Eligible patients will have 1) histologically- or cytologically-confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment, 2) measurable disease based on imaging studies within 28 days before the first dose of study drug, and 3) received 1-2 prior lines of systemic therapy for locally recurrent and/or metastatic disease. Previous treatment with a PD-1/PD-L1-blocking antibody or a HDAC inhibitor is not permitted.
Specific Aims: In Phase 2, the primary endpoint is progression free survival (PFS), as assessed by the investigators using RECIST 1.1. Secondary endpoints include PFS by immune response RECIST (irRECIST), overall response rate, clinical benefit rate, overall survival, safety, and duration and time to response for those patients achieving a complete or partial response. Exploratory endpoints include PK, protein lysine acetylation, and immune correlates.
Statistical Methods: The primary analysis of PFS will be performed using a stratified log-rank test. Estimation of the hazard ratio for treatment effect will be determined using a stratified Cox proportional hazards model. 60 PFS events are estimated to provide 80% power to detect the targeted improvement in PFS with one-sided significance level of 0.1. An independent data safety monitoring board will meet at regular intervals to oversee trial conduct and patient safety.
Accrual: Up to 88 evaluable patients are anticipated if the study completes all phases of evaluation (6-18 patients in Phase 1b, 70 patients in Phase 2). The study was activated in May 2016 (NCT02708680).
Citation Format: Forero A, Stroyakovskiy D, Cha E, Cruickshank S, Hasapidis J, Meyers ML, Slamon DJ. ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-12.
Collapse
Affiliation(s)
- A Forero
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - D Stroyakovskiy
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - E Cha
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - S Cruickshank
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - J Hasapidis
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - ML Meyers
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - DJ Slamon
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| |
Collapse
|
17
|
Hong D, Dowlati A, Burris H, Lee J, Brose M, Farago A, Bauer T, Taylor M, Shaw A, Smith S, Nanda N, Cruickshank S, Cox M, Doebele R. 150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Laetsch T, Nagasubramanian R, Dubois S, Mascarenhas L, Hawkins D, Shukla N, Turpin B, Smith S, Reynolds M, Cruickshank S, Donahue L, Cox M, Pappo A. 164TiP Phase I study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Drilon A, Hong D, Deeken J, Smith S, Reynolds M, Cruickshank S, Deegan M, Ku N, Hyman D. A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Laetsch T, Nagasubramanian R, Dubois S, Mascarenhas L, Hawkins D, Shukla N, Turpin B, Smith S, Reynolds M, Cruickshank S, Donahue L, Cox M, Pappo A. Phase 1 study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Chumsri S, Lee MJ, Tomita Y, Lee S, Tomita S, Cruickshank S, Ordentlich P, Trepel JB. Abstract P2-11-10: Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Entinostat, a class I HDAC inhibitor (HDACi), has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of entinostat + exemestane (EE) vs. exemestane + placebo (EP) in advanced hormone receptor-positive breast cancer progressed on nonsteroidal aromatase inhibitors. ENCORE 301 met the primary progression free survival endpoint and showed a median 8.3-month improvement in the overall survival (OS) exploratory endpoint for the EE arm. Emerging preclinical work suggests that entinostat has immunomodulatory effects and can eradicate modestly immunogenic mouse tumors in combination with immune checkpoint blockade agents via reduction of circulating myeloid-derived suppressor cells (MDSC). Based on these data, we conducted an analysis of immune subsets in blood samples from ENCORE 301 breast cancer patients.
Method: Blood was collected from a subset of 49 patients (27 EE and 22 EP) representative of the 130 patients enrolled in ENCORE 301 on cycle 1 day 1 (C1D1; pre-treatment), C1D2, C1D8, and C1D15 for biomarker analysis. Of these, 34 patient samples (20 EE and 14 EP) were analyzed for circulating immune subsets. The percent change in subsets at C1D15 vs. baseline was assessed based on the following surface markers: Lin-MDSC (lin; CD3, CD19, CD56)-HLA-DR-CD11b+CD33+), granulocytic MDSC (CD14-CD11b+CD33+), monocytic MDSC (Lin-HLA-DR-CD11b+CD33+CD14+), immature MDSC (Lin-HLA-DR-CD11b+CD33+CD14-), CD8+ T-cells (CD4-CD8+), Foxp3-CD4+ T-cells (CD8-CD4+Foxp3-), and Tregs (CD4+CD8-CD25hiFoxp3+). Monocytes were analyzed for three populations: CD14+, CD14+HLA-DRhi, and CD14+HLA-DRlow/negative. In addition, PD-1, CTLA-4, and TIM-3 were measured on T-cell subsets, and CD40 was measured on MDSCs.
Results: In line with preclinical data, we observed a significant reduction in granulocytic MDSC (-14.67% vs. +20.56%, p 0.029) and monocytic MDSC (-62.3% vs. +1.97%, p 0.002) in EE. Entinostat did not alter immature MDSC levels (-20.9% vs. -15.0%, p 0.93) suggesting a downstream effect of entinostat on MDSC subsets. Interestingly, CD40, a costimulatory receptor required for MDSC-mediated immune suppression was significantly down-regulated in all MDSC subsets except granulocytic MDSC where a downward trend was observed. Entinostat did not significantly impact the ratio of CD8+ T-cells per CD4+ T-cells or per Tregs or alter expression of CTLA4, PD-1, or TIM3 on T-cell subsets. Reduced expression of HLA-DR on monocytes has been associated with poor prognosis in cancer. Consistent with entinostat-mediated immunomodulatory effects, a significant increase in the number of HLA-DR+ monocytes (34.1% vs. -11.38%, p 0.0004) and level of HLA-DR expression on monocytes (16.3% vs. -4.7%; p 0.015) was observed.
Conclusion: Data with entinostat combined with exemestane in ENCORE 301 provide the first evidence of HDACi-mediated reduction of immunosuppressive MDSCs and increased immunocompetent CD14+HLA-DRhi monocytes in patients. These findings may explain the improved OS seen with EE in ENCORE 301 and provide strong rationale for planned combination studies of entinostat with immune checkpoint blockade agents.
Citation Format: Chumsri S, Lee M-J, Tomita Y, Lee S, Tomita S, Cruickshank S, Ordentlich P, Trepel JB. Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-10.
Collapse
Affiliation(s)
- S Chumsri
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - M-J Lee
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - Y Tomita
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - S Lee
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - S Tomita
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - S Cruickshank
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - P Ordentlich
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - JB Trepel
- Mayo Clinic, Jacksonville, FL; National Cancer Institute, Bethesda, MD; Syndax Pharmaceuticals, Inc., Waltham, MA
| |
Collapse
|
22
|
Yardley DA, Melisko ME, Forero A, Telli M, Cruickshank S, Green J, Yellin M, Davis T, Vahdat LT. Abstract OT2-6-16: A pivotal multicenter, randomized, study evaluating the novel antibody-drug conjugate CDX-011 in patients with metastatic, triple-negative, high GPNMB over-expressing breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot2-6-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: GPNMB is an internalizable transmembrane glycoprotein overexpressed in multiple tumor types where it is a poor prognostic factor. Its functions appear to include mediating intercellular adhesion, promoting tissue repair, and regulating cell growth and differentiation. In tumor cell lines including breast cancer (BC), GPNMB enhances tumor growth and bone metastases. Relative to other BC subtypes, triple-negative BC (TNBC) highly over-expresses GPNMB in tumor epithelium where it correlates with a higher risk of recurrence. CDX-011 (glembatumumab vedotin) is a fully human GPNMB-specific monoclonal antibody drug conjugate combining the tumor-targeting GPNMB antibody with the potent cytotoxic microtubule inhibitor, monomethylauristatin E (MMAE). In the Phase II EMERGE study, 122 patients (pts) with heavily pre-treated BC (2-7 priors) and GPNMB-expression by IHC in ≥ 5% of either the tumor epithelial or stromal cells in archival tissue were randomized 2:1 to receive CDX-011 or “investigator's choice” (IC) single-agent chemotherapy, with crossover to CDX-011 permitted. CDX-011 as compared to IC, demonstrated higher objective response rates, with ORR of 8/25 (32%) vs 1/8 (13%) for high GPNMB expression (defined as expression in ≥25% of epithelial tumor cells) and 5/27 (19%) vs. 0/9 (0%) for TNBC. In the presence of both TNBC and high GPNMB, ORR was 4/12 (33%) vs 0/4 (0%) which corresponded to a doubling of median progression-free survival (PFS, p = 0.008) and median overall survival (OS, p = 0.003). CDX-011 was well tolerated with less hematologic toxicity (neutropenia: 29% vs 44%; leukopenia: 10% vs 27%; thrombocytopenia: 4% vs. 15%) but more rash (47% vs. 2%) and neuropathy (23% vs 12%) than IC. Methods: The current pivotal study aims to evaluate CDX-011 in metastatic GPNMB-over-expressing TNBC defined as ER and PR < 1%, HER2 negative (0-1+ IHC, or FISH ratio < 1.8). Eligibility criteria include >25% tumor epithelium GPNMB expression by central IHC; taxane and anthracyline resistance; ≤1 prior chemotherapy regimen for advanced BC; measurable disease by RECIST 1:1 and no persistent treatment-related toxicity of ≥ Grade 2 severity. 300 pts will be randomized (2:1) to receive CDX-011 (1.88 mg/kg IV q 21 days) or capecitabine (2500 mg/m2 daily for d1-14, q21 days) until progression or toxicity. Disease assessments are performed every six weeks for 6 months, and every 12 weeks thereafter. All pts are subsequently followed for survival. Endpoints are ORR and PFS (co-primary), duration of response, OS, safety, pharmacokinetics, and quality of life; tumor response assessments will be assessed by central review per RECIST 1.1. The trial has 80% power to detect a hazard ratio of 0.64 for PFS with α = 0.01 and/or a 30% increase in ORR (from 15% to 30%) with α = 0.04. For further information, contact info@celldextherapeutics.com.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT2-6-16.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - ME Melisko
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - A Forero
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - M Telli
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - S Cruickshank
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - J Green
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - M Yellin
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - T Davis
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| | - LT Vahdat
- Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN
| |
Collapse
|
23
|
Boasberg PD, Weber RW, Cruickshank S, Hamid O, O'Day S, Spitler LE. Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Garratt CJ, Elliott P, Behr E, Camm AJ, Cowan C, Cruickshank S, Grace A, Griffith MJ, Jolly A, Lambiase P, McKeown P, O'Callagan P, Stuart G, Watkins H. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010; 12:1156-75. [DOI: 10.1093/europace/euq261] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
|
25
|
Boasberg P, Cruickshank S, Hamid O, O'Day S, Weber R, Spitler L. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9061] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9061^ Background: Nab-paclitaxel (Abraxane) increases intra-tumoral concentrations of paclitaxel and has efficacy superior to that of paclitaxel for the treatment of metastatic breast cancer (J Clin Oncol 2005:23:7794–7803). Nab-paclitaxel demonstrated single agent activity in metastatic melanoma. (ASCO 2005:7558) Bevacizumab is a monoclonal antibody that targets VEGF resulting in inhibition of tumor angiogenesis and enhances tumor response to paclitaxel. (NEJM 2007:357:2666–2676) Methods: Eligible were chemotherapy-naïve patients with unresectable stage III or IV melanoma, ECOG performance status of 0–1, and adequate organ function. The treatment regimen was given in a 28-day cycle in which nab-paclitaxel 150 mg/m2 was administered on days 1, 8, and 15 and bevacizumab 10mg/kg on days 1 and 15 until disease progression or dose limiting toxicity. Response assessments were made by RECIST criteria every 2 cycles. Results: Forty-one patients have been treated since 08/15/07. Over 50% of the patients had stage IV, MIc disease. The median duration of follow-up for progression-free survival from start of protocol treatment is 5.3 months. Progression-free survival at 4 months is 83%,(95%CI:69%-97%). Median progression free survival is 6.25 months (95%CI: 5.63–9.41). The median duration of follow-up for survival is 4.7 months. Three patients have died and 38 patients remain alive. The 6 month survival rate is 91% (95%CI:79%-100%).The 12 month survival rate is 83% (95% CI:65%-100%). The median duration of overall survival has not been reached yet. Dose modifying toxicities consisted primarily of neutropenia, neuropathy, and hypertension. Conclusions: Early experience suggests that nab-paclitaxel and bevacizumab is an effective and well-tolerated regimen as first-line therapy in patients with metastatic melanoma. The study is ongoing with an accrual target of 50 patients. [Table: see text] ASCO Conflict of Interest Policy and Exceptions In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2009 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest .
Collapse
Affiliation(s)
- P. Boasberg
- The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica, CA; N. Ca. Melanoma Center at St. Mary's Medical Center, San Francisco, CA
| | - S. Cruickshank
- The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica, CA; N. Ca. Melanoma Center at St. Mary's Medical Center, San Francisco, CA
| | - O. Hamid
- The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica, CA; N. Ca. Melanoma Center at St. Mary's Medical Center, San Francisco, CA
| | - S. O'Day
- The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica, CA; N. Ca. Melanoma Center at St. Mary's Medical Center, San Francisco, CA
| | - R. Weber
- The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica, CA; N. Ca. Melanoma Center at St. Mary's Medical Center, San Francisco, CA
| | - L. Spitler
- The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica, CA; N. Ca. Melanoma Center at St. Mary's Medical Center, San Francisco, CA
| |
Collapse
|
26
|
Spitler LE, Weber RW, Cruickshank S, Whiteside TL. Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20004 Background: Our previous study suggested that administration of GM-CSF to high-risk melanoma patients may prolong survival (JCO 18(8):1614–1621, 2000) and led to a prospective randomized trial (E4697). This study has completed accrual and follow-up is now ongoing. Simultaneously, we conducted a follow-on study to gain further information about the immunological effects and clinical outcomes of adjuvant GM-CSF therapy of melanoma. Methods: GM-CSF, 125 μg/m2, was administered subcutaneously in 28-day cycles of 14 days on/14 days off for 1 year. Blood draws were keyed to GM-CSF administration: Days 0 (before), 15 (after 14 days on GM-CSF), 29 (after 14 days off GM-CSF), 155 and 351 (after 14 days on GM-CSF in the 6th and 13th cycle). Forty- nine patients were evaluable for immunologic responses on Day 15. Immunophenotyping of the white cell population was done on a subset consisting of 6 patients. Results: In 42 patients, there was an increase in the WBC counts to above normal after 14 days of GM-CSF therapy in the first cycle. This increase did not occur in 7 patients and these patients had a significantly shorter survival. There was a similar increase in neopterin levels following 14 days of GM-CSF administration, which returned to baseline after 14 days off therapy and did not correlate with clinical outcome. Immunophenotypic analysis showed an increase in activated and regulatory T cells and a decrease in the percent of CD11c+DC (myeloid) cells in the 6 patients evaluated, all returning to baseline on Day 29. Conclusions: GM-CSF therapy was associated an increase in the WBC counts in the majority of patients after 14 days of treatment and patients who did not experience this increase had a significantly shorter life expectancy. The observed increase in neopterin levels is consistent with macrophage activation as the potential mechanism of action of adjuvant GM-CSF administration. Additional immunologic effects which may play a role during GM-CSF therapy include the increase in activated T-cells and decrease in CD11c+DC, which may be moving from the peripheral circulation into the tissues. [Table: see text]
Collapse
Affiliation(s)
- L. E. Spitler
- Northern California Melanoma Center, San Francisco, CA; Scott Cruickshank & Associates, Santa Barbara, CA; University of Pittsburgh, Pittsburgh, PA
| | - R. W. Weber
- Northern California Melanoma Center, San Francisco, CA; Scott Cruickshank & Associates, Santa Barbara, CA; University of Pittsburgh, Pittsburgh, PA
| | - S. Cruickshank
- Northern California Melanoma Center, San Francisco, CA; Scott Cruickshank & Associates, Santa Barbara, CA; University of Pittsburgh, Pittsburgh, PA
| | - T. L. Whiteside
- Northern California Melanoma Center, San Francisco, CA; Scott Cruickshank & Associates, Santa Barbara, CA; University of Pittsburgh, Pittsburgh, PA
| |
Collapse
|
27
|
Jagannath S, Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T, Trudel S, Taylor J, Fuhrman D, Cruickshank S, Schwartz R, Kunkel L, Siegel D. A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003). ACTA ACUST UNITED AC 2009. [DOI: 10.1016/s1557-9190(11)70562-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Spitler LE, Weber RW, Cruickshank S, Thompson JF, Lin H, Soong SJ, Garbe E, Ernstoff MS, Grossbard ML, Markovic SN, Whiteside TL. Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) as adjuvant therapy of melanoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Abstract
BACKGROUND Breast Care Nurses (BCNs) are now established internationally, predominantly in well resourced healthcare systems. The role of BCNs has expanded to reflect the diversity of the population in which they work, and the improvements in survival of women with breast cancer. Interventions by BCNs aim to support women and help them cope with the impact of the disease on their quality of life. OBJECTIVES To assess the effectiveness of individual interventions carried out by BCN's on quality of life outcomes for women with breast cancer. SEARCH STRATEGY We searched the Cochrane Breast Cancer Group Specialised Register and the Cochrane Central Register of Controlled Trials (15 January 2007). We also searched MEDLINE (1966 to September 2006), CINAHL (1982 to September 2006), EMBASE (1980 to September 2006), British Nursing Index (1984 to September 2006), CancerLit (1961 to September 2006), PsycInfo (1967 to September 2006), Library and Info Science Abstracts (LISA) (1969 to September 2006), Dissertation Abstracts International (only available 2005 to September 2006). We contacted authors as appropriate. SELECTION CRITERIA Randomised controlled trials assessing the effects of interventions carried out by BCN's on quality of life outcomes, for women with breast cancer. DATA COLLECTION AND ANALYSIS Two authors independently assessed relevant studies for inclusion and undertook data extraction and quality assessment of included studies. MAIN RESULTS We incuded five studies, categorised into three groups. Three studies assessing psychosocial nursing interventions around diagnosis and early treatment found that the BCN could affect some components of quality of life, such as anxiety and early recognition of depressive symptoms. However, their impact on social and functional aspects of the disease trajectory was inconclusive. Supportive care interventions during radiotherapy was assessed by one study which showed that specific BCN interventions can alleviate perceived distress during radiotherapy treatment, but did not improve coping skills, mood or overall quality of life. One study assessed nurse-led follow-up interventions in which no statistically significant difference was identified for main demographic variables, satisfaction with care, access to medical care or anxiety and depression. AUTHORS' CONCLUSIONS There is limited evidence at this time to support the contention that interventions by BCNs assist in the short-term with the recognition and management of psychological distress for women with breast cancer. Further research is required before the impact of BCNs on aspects of quality of life for women with breast cancer can be known.
Collapse
Affiliation(s)
- S Cruickshank
- Napier University, School of Acute and Continuing Care Nursing, Canaan Lane Campus, 74 Canaan Lane, Edinburgh, Lothian, UK, EH9 2TB.
| | | | | | | | | |
Collapse
|
30
|
Abstract
BACKGROUND The method of delivering a diagnosis of breast cancer to women has the potential to impact on their level of interpretation, patient recall and satisfaction. OBJECTIVES To assess the effectiveness of different methods when used to communicate a primary diagnosis of breast cancer to women. SEARCH STRATEGY We searched the Cochrane Breast Cancer Group Specialised Register on 7 September 2006, Cochrane Consumers and Communication Group on 27 October 2006, MEDLINE (1966 to present), CINAHL (1982 to present), EMBASE OVID (1980 to present), British Nursing Index (Jan 1984 to present), PsycInfo (1967 to present), Dissertation Abstracts International (2004 to 2006), Library and Info Science Abstracts (LISA) (1969 to present), ISI Web of Knowledge (conference abstracts) and reference lists of articles. SELECTION CRITERIA We sought randomised controlled trials of women with a histologically confirmed diagnosis of breast cancer being given a diagnosis of primary breast cancer. Trials should also have used one or more of the following methods; face-to-face consultations, written information, telephone consultation, audio or video tapes of consultation. DATA COLLECTION AND ANALYSIS Two review authors independently assessed trials for inclusion in the review. Studies were to be assessed using standardised data extraction and quality assessment forms. MAIN RESULTS The search strategies identified 2847 citations overall. A total of 30 citations appeared relevant however there were three duplicates which left 27 articles for further review. Articles reporting the same primary data accounted for 6 of the publications Brown 1997; Brown 1998; Brown 1999; Brown 2000; Hack 2000; Hack 2003 which left 23 original papers to be reviewed for inclusion. Of these, none met the inclusion criteria. Data extraction and assessment of methodological quality was therefore not possible. AUTHORS' CONCLUSIONS The review question remains unanswered as there were no randomised trials of methods of communicating a diagnosis of breast cancer to women. The authors have considered the possible reasons for the lack of research studies in this area and have considered that it is perhaps unethical to randomise women at such a vulnerable time such as waiting for a diagnosis. The design of ethically sensitive research to examine this topic needs to be explored to inform future practice. As some papers reviewed by the authors related to the first consultation visit, where treatment options are discussed, perhaps a review which focused on the methods of communication at the first consultation visit would provide more reliable evidence for the effectiveness of methods of communication and overcome the ethical dilemmas previously mentioned.
Collapse
Affiliation(s)
- K Lockhart
- Napier University, School of Nursing Midwifery & Social Care, Canaan Lane Campus, Edinburgh, Lothian, UK, EH10 4TB.
| | | | | | | |
Collapse
|
31
|
Greenway FL, Martin CK, Gupta AK, Cruickshank S, Whitehouse J, DeYoung L, Kamdar K, Caruso MK, Roberts AT, England M, Dumas K, Laidlaw BJF, Rogers B, Cowley MA. Using intranasal lidocaine to reduce food intake. Int J Obes (Lond) 2006; 31:858-63. [PMID: 17130849 DOI: 10.1038/sj.ijo.0803506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Develop a dose-response curve for the effect of intranasal lidocaine on food intake. DESIGN Healthy obese subjects had food intake, ratings of hunger, desire to eat, craving and fullness measured at lunch after an overnight fast. Four treatments were given as nose drops (0.5-0.6 ml per nostril) 5 min before the meal in a double-blind manner with a four period crossover design including a 7-day washout between periods. The treatments were saline, 2.5, 10 and 25 mg lidocaine per nostril. The order of administration was randomly assigned to each subject. Electrocardiograms, vital signs, chemistry panels, complete blood counts (CBC) and nasal inspections were carried out before and after each dose. SUBJECTS Forty-seven subjects were screened, 34 were randomized and 20 subjects completed all four study periods in the trial. The subjects were 39+/-12.5 (s.d) years of age, had a weight of 91+/-13.0 kg, a height of 167+/-10.3 cm, 56% were women, 47% were African-American and 53% were Caucasian. MEASUREMENTS Food intake, rating of hunger, desire to eat, craving and fullness are measures of efficacy. Adverse events, electrocardiograms, vital signs, chemistry panels, nasal inspections, CBC and physical exams are measures of safety. RESULTS The mean reduction in food intake vs saline control in the 20 subjects completing all four study periods was 3.3+/-7% (s.d), 4.2+/-8.5% and 7.4+/-7.3% in the 2.5 mg, 10 and 25 mg per nostril groups, respectively (P=NS). Hunger and desire to eat in subjects who completed at least one study period decreased dose dependently (P<0.03, at the 25 mg per nostril dose). There were no clinically significant changes in safety measures, electrocardiograms, vital signs, chemistry panels, CBC or nasal inspections. CONCLUSION Intranasal lidocaine reduced hunger and the desire to eat, but this did not translate into a significant reduction in food intake suggesting that intranasal lidocaine will not have value in treating obesity.
Collapse
Affiliation(s)
- F L Greenway
- Outpatient Clinic Unit, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
McDonald G, Cruickshank S, Rodell T, Hockenbery D. Oral beclomethasone dipropionate (BDP) for gastrointestinal GVHD: A corticosteroid-sparing treatment with improved survival at day +200. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether JD, Henner WMD, Chi KN, Cruickshank S. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4516] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. M. Beer
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - C. W. Ryan
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - P. M. Venner
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - D. P. Petrylak
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - G. Chatta
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - J. D. Ruether
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - W. M. D. Henner
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - K. N. Chi
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| | - S. Cruickshank
- Oregon Health & Science Univ, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Columbia Presbyterian Med, New York, NY; Univ of Pittsburgh, Pittsburgh, PA; Tom Baker Cancer Ctr, Calgary, AB, Canada; Novacea, Inc., South San Francisco, CA; BC Cancer Agency, Vancouver, BC, Canada; Scott Cruickshank, Santa Barbara, CA
| |
Collapse
|
34
|
|
35
|
Fields KK, Crump M, Bence-Bruckler I, Bernstein S, Williams S, Frankel S, Miller A, Demetri G, Nabholtz JM, Cruickshank S, Lill M. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2000; 26:1083-8. [PMID: 11108307 DOI: 10.1038/sj.bmt.1702662] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This paper summarizes a pilot, sequential dose-escalation study of PEG-rHuMGDF in patients with advanced malignancies who had delayed platelet recovery after autologous stem cell transplantation (ASCT). Patients were randomized to receive either placebo (n = 11) or PEG-rHuMGDF at 5 (n = 9), 10 (n = 6), or 25 (n = 7) microg/kg/day by subcutaneous injection for 14 days and were monitored for 5 weeks. Across all treatment groups, eight patients had platelet recovery to > or = 20 x 10(9)/l by day 21. The proportion of patients achieving platelet recovery, the median number of days and units of platelet transfusions were similar for the placebo and the PEG-rHuMGDF groups. PEG-rHuMGDF was well tolerated at all dosages. The incidence rates of adverse events in all groups were similar. No deaths on study, no drug-related serious adverse events, and no development of neutralizing antibodies to MGDF occurred.
Collapse
Affiliation(s)
- K K Fields
- H Lee Moffitt Cancer Center, Tampa, FL 33617, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000; 26:141-5. [PMID: 10918423 DOI: 10.1038/sj.bmt.1702465] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Forty-seven patients with stage II, III, or IV breast cancer undergoing autologous peripheral blood progenitor cell (PBPC) transplantation were randomized to placebo (n = 13) or to one of five sequential dose cohorts of pegylated (PEG) recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) (1.0, 2.5, 5.0, 7.5, or 10.0 microg/kg/day) (n= 34). Blinded study drug was started on the day of transplantation and was continued until the platelet count was > or =100 x 109/l or a maximum of 21 days. PBPCs were mobilized with filgrastim (r-metHuG-CSF) and all patients received filgrastim starting on day +2 after transplantation. The nadir platelet count was not affected by treatment. The median time to platelet recovery was 11 and 12 days for the placebo and combined PEG-rHuMGDF groups, respectively. No trends in adverse events suggested dose- or treatment-related toxicity. Two patients withdrew from the study because of an adverse event (allergic reaction in the 7.5 microg/kg group) probably related to study drug, and veno-occlusive disease (VOD) (in the 5 microg/kg group) which was felt not to be related to study drug by the investigator. No patients developed neutralizing antibodies to MGDF. Day +21 and day +28 platelet counts were higher in the group receiving PEG-rHuMGDF (246 vs 148 x 109/l and 299 vs 145 x 109/l, respectively; both P < 0. 05). PEG-rHuMGDF up to 10 microg/kg/day was well tolerated. In this study, there was no effect of study drug on initial platelet engraftment at the doses studied. However, the efficacy of other doses is unknown.
Collapse
Affiliation(s)
- B Bolwell
- The Cleveland Clinic Foundation, OH 44195, USA
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Cruickshank S. Regulation of immune recognition elements by normal human biliary epithelial cells by pro- and anti-inflammatory cytokines. Immunol Lett 1997. [DOI: 10.1016/s0165-2478(97)88497-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Cruickshank S, Southgate J, Trejdosiewicz L. Regulation of immune recognition elements by normal human biliary epithelial cells by pro- and anti-inflammatory cytokines. Immunol Lett 1997. [DOI: 10.1016/s0165-2478(97)86657-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:492-501. [PMID: 7520676 DOI: 10.7326/0003-4819-121-7-199410010-00004] [Citation(s) in RCA: 168] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
OBJECTIVE To determine if filgrastim (recombinant human methionyl granulocyte colony-stimulating factor) used in addition to standard inpatient antibiotic therapy accelerated recovery from infection associated with chemotherapy-induced neutropenia. DESIGN Randomized, double-blind, placebo-controlled trial. SETTING Hematology and oncology wards of four teaching hospitals. PATIENTS 218 patients with cancer who had fever (temperature > 38.2 degrees C) and neutropenia (neutrophil count < 1.0 x 10(9)/L) after chemotherapy. INTERVENTION Patients were randomly assigned to receive filgrastim (12 micrograms/kg of body weight per day) (n = 109) or placebo (n = 107) beginning within 12 hours of empiric therapy with tobramycin and piperacillin. Patients received treatment and remained in the study until the neutrophil count was greater than 0.5 x 10(9)/L and until 4 days without fever (temperature < 37.5 degrees C) had elapsed. MEASUREMENTS Days of neutropenia and fever and days in the study (hospitalization); time to resolution of fever and febrile neutropenia; and frequency of the use of alternative antibiotics. RESULTS Compared with placebo, filgrastim reduced the median number of days of neutropenia (3.0 compared with 4.0 days of a neutrophil count of < 0.5 x 10(9)/L; P = 0.005) and the time to resolution of febrile neutropenia (5.0 compared with 6.0 days; P = 0.01) but not days of fever (3.0 days for both groups). The frequency of the use of alternative antibiotics was similar in the two groups (46% compared with 41%; P = 0.48). The median number of days patients were hospitalized while on study was the same (8.0 days; P = 0.09); however, filgrastim decreased the risk for prolonged hospitalization (> 11 days, 4th quartile) by half (relative risk, 2.1 [95% CI, 1.1 to 4.1]; P = 0.02). In exploratory subset analyses, filgrastim appeared to provide the greatest benefit in patients with documented infection and in patients presenting with neutrophil counts of less than 0.1 x 10(9)/L. CONCLUSIONS Filgrastim treatment used with antibiotics at the onset of febrile neutropenia in patients with cancer who have received chemotherapy accelerated neutrophil recovery and shortened the duration of febrile neutropenia.
Collapse
Affiliation(s)
- D W Maher
- Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|